Skip to main content

ORIGINAL RESEARCH article

Front. Pain Res.
Sec. Pharmacological Treatment of Pain
Volume 6 - 2025 | doi: 10.3389/fpain.2025.1527371

Evaluation of long-term outcomes with intrathecal opioid treatment: A comparison utilizing comparative data derived from pain clinic populations in Australia and New Zealand

Provisionally accepted
Elouise Rose Comber Elouise Rose Comber 1Jenny Strong Jenny Strong 2Orla Moore Orla Moore 3*Asaduzzaman Khan Asaduzzaman Khan 2James O'Callaghan James O'Callaghan 4*Benjamin Manion Benjamin Manion 4*Brendan Joseph Moore Brendan Joseph Moore 4*Maree Therese Smith Maree Therese Smith 5*
  • 1 School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
  • 2 School of Health and Rehabilitation Sciences, Faculty of Health and Behavioural Sciences, The University of Queensland, St Lucia, Queensland, Australia
  • 3 School of Clinical Medicine, Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia
  • 4 Axxon Pain Medicine, Brisbane, Queensland, Australia
  • 5 Centre for Integrated Preclinical Drug Development, School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia

The final, formatted version of the article will be published soon.

    An obstacle to analysis of the long-term effectiveness of intrathecal (IT) opioids is absence of historical patient baseline data. The electronic Persistent Pain Outcomes Collaboration (ePPOC) is an initiative of the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists. Recently published ePPOC data has provided justifiable surrogate baseline data allowing opportunities for pain outcomes research into select patient treatment groups. Our aim was to compare long-term outcomes of IT opioid therapy with a surrogate baseline utilizing a large ePPOC data set for patients at the time of initial presentation to 36 pain clinics in Australia and New Zealand. Study participants were 49 consenting patients receiving IT opioids as part of a long-term pain management regime for treating chronic non-cancer pain. Their data were compared with the large ePPOC data set (n=13,343). The questionnaires comprised a demographic questionnaire, the Brief Pain Inventory, the Depression, Anxiety and Stress Scale, the Pain Catastrophizing Questionnaire, and the Pain Self-Efficacy Questionnaire. Compared with the ePOCC group, participants who received IT opioids long-term for the relief of chronic non-cancer pain reported significantly lower (p≤0.001) pain severity (4.3 vs 6.4), and pain interference scores (5.5 vs 7), significantly lower depression (20.2 vs 13.7), anxiety (9.6 vs 14.1), stress (15.5 vs 21), rumination (6.9 vs 10), magnification (3.8 vs 5.9), helplessness (9.7 vs 14.1), general catastrophizing (20.4 vs 29.8), and higher self-efficacy (29.5 vs 20.7). The observed improvements in all measured pain variables have occurred in the context of comprehensive pain management, and therefore, may be attributable to pain reduction and not directly to IT opioid use or the device itself. Favourable pain management outcomes, in a select patient treatment group utilizing long-term IT opioid therapy, were demonstrated using the large-data ePPOC initiative, highlighting the research opportunities it provides.

    Keywords: intrathecal (IT), opioid, electronic Persistent Pain Outcomes Collaboration (ePPOC), Psychosocial outcomes, longterm IT opioid, Chronic non-cancer pain

    Received: 13 Nov 2024; Accepted: 31 Jan 2025.

    Copyright: © 2025 Comber, Strong, Moore, Khan, O'Callaghan, Manion, Moore and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Orla Moore, School of Clinical Medicine, Faculty of Medicine, The University of Queensland, St Lucia, 4072, Queensland, Australia
    James O'Callaghan, Axxon Pain Medicine, Brisbane, Queensland, Australia
    Benjamin Manion, Axxon Pain Medicine, Brisbane, Queensland, Australia
    Brendan Joseph Moore, Axxon Pain Medicine, Brisbane, Queensland, Australia
    Maree Therese Smith, Centre for Integrated Preclinical Drug Development, School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, 4072, Queensland, Australia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.